Rocket Pharmaceuticals

175 articles about Rocket Pharmaceuticals

• Rocket Pharmaceuticals and REGENXBIO Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

  11/26/2018

  Rocket (Nasdaq:RCKT), a leading U.S.-based multi-platform gene therapy company, andREGENXBIO (Nasdaq:RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced an exclusive, worldwide license agreement for Rocket to develop and commercialize gene therapy treatments for Danon disease

• Rocket Pharmaceuticals Announces Preclinical Data for AAV-Based RP-A501, the First Investigational Gene Therapy Program for a Monogenic Heart Failure Syndrome

  11/26/2018

  Preclinical Data Package Shows Dose-Dependent Survival, Functional, Structural, and Molecular Benefits with No Safety or Tolerability Issues Observed

• REGENXBIO and Rocket Pharmaceuticals Announce New License Agreement for the Treatment of Danon Disease Using NAV AAV9 Vector

  11/26/2018

  REGENXBIO grants Rocket exclusive, worldwide rights to NAV AAV9 for the development and commercialization of treatments for Danon Disease

• Rocket Pharmaceuticals Announces Proposed Public Offering of $50,000,000 Shares of its Common Stock

  11/26/2018

  Rocket Pharmaceuticals, Inc. today announced that it has commenced an underwritten public offering of $50,000,000 of shares of its common stock.

• Rocket Pharmaceuticals Announces FDA Clearance of IND Application for RP-L102 Gene Therapy for Fanconi Anemia

  11/7/2018

  Rocket Pharma (Nasdaq: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, announces the clearance of the Company’s Investigational New Drug (IND) application for RP-L102, the Company’s lentiviral vector (LVV)-based gene therapy for the treatment of Fanconi Anemia (FA), by the U.S. Food and Drug Administration (FDA).

• Rocket Pharmaceuticals Reports Third Quarter 2018 Financial Results and Operational Highlights

  11/7/2018

  Fanconi Anemia (FA) Data Presented at ESGCT Shows Increasing and Durable Engraftment for up to 30 Months with First Generation Product

• Rocket Pharmaceuticals Announces Participation at Upcoming Conferences

  11/1/2018

  Rocket Pharmaceuticals is a leading U.S.-based multi-platform gene therapy company

• Rocket Pharmaceuticals Presents Preclinical Data at the 2018 Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)

  10/19/2018

  Promising Preclinical Results from Leukocyte Adhesion Deficiency-I and Infantile Malignant Osteopetrosis Programs

• Rocket Pharmaceuticals Announces Participation at Upcoming October 2018 Conferences

  9/25/2018

  Gaurav Shah, M.D., Chief Executive Officer, Invited as Panel Member at The Galien Forum USA 2018

• Rocket Pharmaceuticals Announces Participation at Upcoming September 2018 Investor Conferences

  8/30/2018

  Rocket Pharmaceuticals, Inc. today announced that members of Rocket’s executive team will participate in the following upcoming investor conferences:

• Rocket Pharmaceuticals Reports Second Quarter 2018 Financial Results and Operational Highlights

  8/8/2018

  Achieved Regulatory Designations for Fanconi Anemia (FA) in the U.S. and Europe; Registrational Trial on Track for 2019

• Rocket Pharmaceuticals to Join Russell 3000® and 2000® Indexes

  6/22/2018

  The newly reconstituted indexes take effect after the close on Friday, June 22, 2018.

• Rocket Pharmaceuticals to Present at the Jefferies 2018 Healthcare Conference

  5/30/2018

  Rocket Pharmaceuticals, Inc. announced that Gaurav Shah, M.D., Chief Executive Officer and President of Rocket, will present at the Jefferies 2018 Healthcare Conference.

• 

  CEOs, Directors and Other Senior Executives Tapped by Biotech

  5/21/2018

  Pharma and biotech companies across the globe continued to expand and reshape their leadership teams with new hires this past week. BioSpace collected several announced leadership appointments, which includes new chief executive officers, new members to boards of directors and more.

• Rocket Pharmaceuticals Appoints Gayatri R. Rao, M.D., J.D., Former U.S. Food and Drug Administration Director of the Office of Orphan Products Development, as Vice President, Regulatory Policy and Patient Advocacy

  5/15/2018

  Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) (“Rocket”), a leading U.S.-based multi-platform gene therapy company, today announced the appointment of Gayatri R. Rao, M.D., J.D., as Vice President, Regulatory Policy and Patient Advocacy.